Gsk Plc · LSE:GSK
Gsk — GlaxoSmithKline — Q1 2001 Earnings Presentation
8 slides from Gsk's earnings presentation, Apr 24, 2001
Slide 1: First Quarter Results Presentation to Media
First Quarter Results Presentation to Media 24th April 2001
Slide 2: Integration Update
Integration Update • New organisation up and running! • Merger savings in line with expectations to save at least £400m in 2001 • Integration costs of £346m incurred • Strong pharmaceutical sales momentum 2
Slide 3: First Quarter Financial Results
First Quarter Financial Results Q101 % change Business Performance £m CER Reported Sales 4,757 9 16 - Pharmaceuticals 3,982 11* - Consumer Healthcare 775 (2)* Profit before tax 1,388 11 19 Earnings per ordinary share 16.2p 13 22 Earnings per ADR $0.47 13 9 * % change excludes products divested in 20
Slide 4: Pharmaceuticals - Sales by Region
Pharmaceuticals - Sales by Region % growth - three months ended 31 st March 2001 £815m % share (+10%) USA 51 Europe 28 RoW 21 £2,041m (+14%) £1,126m (+6%) Total sales £3,982 m increase of 11% 4
Slide 5: Drivers of Growth
Drivers of Growth • Seroxat/Paxil: £434m, +17% – Leads worldwide SSRI market – Only SSRI approved for GAD in US • Avandia: £151m, +43% – Leading medicine in category in US – Used by 2 million patients – European launches in Spain, Italy and France • Combivir: £ 145m, +15% 5
Slide 6: Drivers of Growth
Drivers of Growth • Augmentin: £403m, +19% – US sales +31% – New ES and SR formulations • Seretide: £98m, >100% – GSK’s No. 1 selling product in Europe – Advair launched in US 6
Slide 7: New Product Momentum
New Product Momentum Avandia Combivir • New products New vaccines represent 18% of Seretide pharma sales Zyban Coreg • Growing at 34% Ziagen • Contributing Zeffix £727m in sales Hycamtin for the quarter Trizivir Requip Agenerase Products <5 years from launch in a major market 7
Slide 8: Highlights
Highlights • Pharmaceutical sales +11%; US pharma +14% • Paxil +17% and Augmentin +19% • New products +34% to £727m • Respiratory business +21% to £782m • Advair launched 16 April • On track to meet 2001 EPS growth target of around 13% 8